Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

56

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Non-alcoholic Fatty Liver Disease
Liver Cirrhosis

Interventions

DRUG: CC-90001
DRUG: Placebo

Sponsor

Celgene